Streetbeat News

CRDF

Cardiff Oncology, Inc.

https://www.cardiffoncology.com

Industry

Biotechnology

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Open

2.88

Mkt cap

132M

Volume

1.3M

High

2.88

P/E Ratio

-2.72

52-wk high

6.42

Low

2.53

Div yield

N/A

52-wk low

1.07

Health care stocks experienced significant movements in Wednesday's intraday session, with notable gainers including Heron Therapeutics, TRACON Pharma, NuCana, Kintara Therapeutics, Cardiff Oncology, and Annexon, showing increases ranging from 26.36% to 35.4%. On the downside, Trxade Health, Tenon Medical, P3 Health Partners, Envoy Medical, Neumora Therapeutics, and Aesthetic Medical Intl saw declines between 16.28% and 22.6%. These movements were influenced by factors such as Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 5:31 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Cardiff Oncology (NASDAQ:CRDF) and increased the price target from $12 to $14.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 11:49 am

U.S. stocks traded lower with the S&P 500, Dow, and NASDAQ all seeing declines. Super Micro Computer, Inc. (SMCI) is set to join the S&P 500, replacing Zions Bancorporation (ZION). Cardiff Oncology, Inc. (CRDF), Quoin Pharmaceuticals, Ltd. (QNRX), and Renalytix Plc (RNLX) saw their shares rise due to positive company developments. Conversely, BioVie Inc. (BIVI), BioCardia, Inc. (BCDA), and JOANN Inc. (JOAN) experienced significant drops in their share prices. Crude oil prices fell by 1.5%, while gold and silver prices increased.

Portfolio Pulse from Avi Kapoor

March 04, 2024 | 7:34 pm

Bitdeer Technologies Group's shares surged 10.2% after reporting positive Q4 financial results and successful testing of its Bitcoin mining chip, amidst a general rise in Bitcoin prices. Other stocks also saw significant movements, with BitFuFu Inc. leading with a 107% jump following its Nasdaq listing. The session also highlighted FDA approvals, strategic approaches, and financial results as key drivers for stock movements. Conversely, companies like BioVie Inc. and JOANN Inc. faced declines due to public offering pricing and bankruptcy reports, respectively.

Portfolio Pulse from Avi Kapoor

March 04, 2024 | 6:29 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 1%. Energy shares rose by 1.4% as crude oil prices increased by 2.3%. BioVie Inc., Cardiff Oncology, and The RealReal reported significant gains following positive updates. Conversely, Sidus Space, Fisker Inc., and Scilex Holding experienced sharp declines. Fisker's drop was due to preliminary Q4 revenue results below estimates and concerns about its ongoing viability.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 7:32 pm

Zscaler, Inc. (ZS) shares fell by 10.1% following its Q2 earnings report, despite better-than-expected results. Other stocks showed significant movement, with BioVie Inc. (BIVI) and Adial Pharmaceuticals, Inc. (ADIL) among the top gainers. Losers included GigCapital5, Inc. (GIA) and Fisker Inc. (FSR), with FSR dropping 44.6% due to concerns about its going concern status.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 6:19 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals, BioVie, Cardiff Oncology, Myomo, Altamira Therapeutics, and MSP Recovery were among the gainers, with increases ranging from 24.11% to 58.8%. Conversely, Scilex Holding, Precision BioSciences, DermTech, Vivani Medical, Gritstone Bio, and Humacyte saw declines between 20.81% and 36.4%. Notably, Cardiff Oncology and DermTech released their Q4 earnings reports yesterday.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 5:35 pm

The Nasdaq Composite gained around 100 points, with U.S. stocks trading higher. Energy shares rose by 1.6%, while utilities fell by 1.4%. The ISM manufacturing PMI declined to 47.8 in February. BioVie Inc. shares surged 81% after announcing potential improvements for Parkinson's and Alzheimer's patients. Cardiff Oncology's shares rose 38% following positive financial results and clinical updates. Nxu, Inc. shares also gained 38% after a successful Tesla Cybertruck charge. Sidus Space shares dropped 39% after pricing a public offering. Fisker Inc. shares fell 44% due to preliminary revenue results and going concern doubts. Scilex Holding Company shares fell 40% after announcing a bought deal offering.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 5:16 pm

Cardiff Oncology Inc (NASDAQ:CRDF) released data from its discontinued Phase 2 ONSEMBLE trial for second-line RAS-mutated metastatic colorectal cancer, showing efficacy of onvansertib. Despite discontinuing this trial to focus on a first-line treatment program, the company's stock soared by 37.60%. Cardiff Oncology had $75 million in cash at the end of 2023, expected to last until Q3 2025.

Portfolio Pulse from Vandana Singh

March 01, 2024 | 4:38 pm

Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Cardiff Oncology (NASDAQ:CRDF) and increased the price target from $5 to $7.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 3:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.